Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad5f35pp65-stimulated donor-derived cytotoxic T lymphocytes
- Development stage
- Unknown
- Lead developer
- Western Sydney Local Health District
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Ad5f35pp65-stimulated donor-derived cytotoxic T lymphocytes is an investigational adoptive cellular immunotherapy developed to prevent cytomegalovirus (CMV) reactivation in patients following allogeneic hematopoietic stem cell transplantation (HSCT). The therapy involves the ex vivo generation of CMV-specific cytotoxic T lymphocytes (CTLs) from donor peripheral blood. This is achieved by stimulating donor cells with dendritic cells that have been transduced with an adenoviral vector (Ad5f35pp65) encoding the CMV pp65 antigen. The resulting CTLs are then infused into the patient to reconstitute cellular immunity against CMV, targeting and eliminating cells expressing the pp65 protein.
- Other names
- Ad5f35pp65-CTLsAd-5f35pp65-CTLsAd 5f35pp65-CTLsCMV-specific cytotoxic T lymphocytes
02
Targets
pp65/HLA-A*02:01 (CMV pp65 peptide-HLA-A*02:01 complex)pMHC-II (Peptide-major histocompatibility complex class II complex)
Beyond the preview
Go deeper on Ad5f35pp65-stimulated donor-derived cytotoxic T lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad5f35pp65-stimulated donor-derived cytotoxic T lymphocytes.